Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amikacin every 48 hours versus meropenem for urinary tract infection due to E. coli
IRCT20170417033483N2Phase 3Completed
- Sponsor
- Kurdistan University of Medical Sciences
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of amikacin, meropenem and ofloxacin in urinary tract infection (UTI) and uropathogenic Escherichia coli infection (4 arms), sponsored by Kurdistan University of Medical Sciences. Primary endpoint: Treatment of urinary tract infection in patients with positive culture of E. coli during admission. Started May 2017; status: completed.
02
Drugs
amikacinmeropenemofloxacin
03
Conditions
urinary tract infection (UTI)uropathogenic Escherichia coli infection
Beyond the preview
Go deeper on IRCT20170417033483N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170417033483N2.